Kymera Therapeutics Inc. (KYMR) Financial Statements (2024 and earlier)

Company Profile

Business Address 500 NORTH BEACON STREET, 4TH FLOOR
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments374,881407,166442,418296,202
Cash and cash equivalents109,96668,39547,97631,004
Short-term investments264,915338,771394,442265,198
Receivables 15,000  577
Contract with customer, asset, after allowance for credit loss3,7622,537135856
Deferred costs    400
Other undisclosed current assets11,6749,7138,7204,304
Total current assets:405,317419,416451,273302,339
Noncurrent Assets
Operating lease, right-of-use asset52,9458,9099,4269,845
Property, plant and equipment48,13413,33411,88110,841
Long-term investments and receivables61,434152,328125,187162,531
Long-term investments61,434152,328125,187162,531
Restricted cash and investments5,8116,1306,1161,589
Other noncurrent assets2,1183,0172,02230
Total noncurrent assets:170,442183,718154,632184,836
TOTAL ASSETS:575,759603,134605,905487,175
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities40,93931,83726,97614,698
Accounts payable7,0754,3354,0054,368
Accrued liabilities33,86427,50222,97110,330
Deferred revenue37,88335,26061,73992,552
Debt1,2771,4081,138689
Other liabilities524303228106
Other undisclosed current liabilities5,0682,5352,4612,572
Total current liabilities:85,69171,34392,542110,617
Noncurrent Liabilities
Long-term debt and lease obligation1,3011,24614,36414,732
Finance lease, liability1,3011,2461,140604
Liabilities, other than long-term debt93,79640,39439,36177,938
Deferred revenue16,76828,00039,29577,838
Other liabilities  24866100
Operating lease, liability77,02812,14613,22414,128
Total noncurrent liabilities:95,09741,64053,72592,670
Total liabilities:180,788112,983146,267203,287
Equity
Equity, attributable to parent394,971490,151459,638283,888
Common stock6654
Additional paid in capital926,269878,884689,275412,777
Accumulated other comprehensive loss(552)(4,949)(660)(128)
Accumulated deficit(530,752)(383,790)(228,982)(128,765)
Total equity:394,971490,151459,638283,888
TOTAL LIABILITIES AND EQUITY:575,759603,134605,905487,175

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues78,59246,82672,83234,034
Gross profit:78,59246,82672,83234,034
Operating expenses(244,122)(208,082)(173,362)(80,338)
Operating loss:(165,530)(161,256)(100,530)(46,304)
Nonoperating income
(Other Nonoperating income)
18,5686,448313711
Interest and debt expense(181)(179)(158)(121)
Loss from continuing operations before income taxes:(147,143)(154,987)(100,375)(45,714)
Other undisclosed income from continuing operations    
Loss from continuing operations:(147,143)(154,987)(100,375)(45,714)
Loss before gain (loss) on sale of properties:(100,375)(45,714)
Other undisclosed net income (loss)181179158121
Net loss:(146,962)(154,808)(100,217)(45,593)
Other undisclosed net income attributable to parent    
Net loss attributable to parent:(146,962)(154,808)(100,217)(45,593)
Preferred stock dividends and other adjustments    (9,050)
Net loss available to common stockholders, diluted:(146,962)(154,808)(100,217)(54,643)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(146,962)(154,808)(100,217)(45,593)
Comprehensive loss:(146,962)(154,808)(100,217)(45,593)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent4,397(4,289)(532)(134)
Comprehensive loss, net of tax, attributable to parent:(142,565)(159,097)(100,749)(45,727)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: